- Supported exchanges /
- KQ /
- 204840.KQ
IBKS No2 SPAC (204840 KQ) stock market data APIs
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further, it provides Cabalin CR extended-release tablet and Jample Ibufen syrup for the nervous system and sensory organs; Gisoren tablets for individual organs, digestive system, and peptic ulcer drugs; and Genstring Troki for treating individual organs and digestive system, as well as oral use. GL Pharm Tech Corp. was founded in 2002 and is headquartered in Seongnam-si, South Korea.
IBKS No2 SPAC Financial Data Overview
| 1028 | |
| 1000 | |
| - | |
| 1067 | |
| 978 | |
| 974-1589 | |
| 76 316 M | |
| 76 699 K | |
| 27 909 M | |
| -8.8747 | |
| 1.016 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
IBKS No2 SPAC Fundamental Data is available in our Financial Data APIs
- Net Revenue 27 909 M
- EBITDA -1 623 062 528
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get IBKS No2 SPAC Earnings via APIs
- Latest Release 2024-06-30
- EPS/Forecast NaN
Get IBKS No2 SPAC End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
